ALK CEO: Slow progress in the US has nothing to do with the allergy business

Danish allergy group ALK is still waiting for a real breakthrough in the US but it has nothing to do with the company's tablets or the allergy business, says the CEO, who instead points to postponed orders and calls ALK's entry to the US market a "long journey."

Photo: Niels Ahlmann Olesen / Ritzau Scanpix

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles